Pharmacologically, strategies targeting CB1/TRPV1 have shown promising therapeutic results in models of pain, spasticity, arthritis, and dyskinesia (Di Marzo et al., 2001, 2002; Brooks et al., 2002; Morgese et al., 2007; Lowin and Straub, 2015) For instance, arvanil, a CB1 agonist, TRPV1 activator, and potent inhibitor of anandamide (AEA) accumulation, alleviates hyperkinesia typical of Huntington’s disease (De Lago et al., 2005). This evidence concerns the gene TRPV1 and juvenile Huntington disease.